Tevogen Inc. (TVGN): R&D Expense
$11.11M
Year ended 2025-12-31
$11.63M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.11M | -64.2% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $31.03M | +604.7% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $4.40M | n/a | 2025-04-02, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tevogen Inc. (TVGN) | 2025-12-31 | $11.11M | -64.2% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $3.06M | -14.6% |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $4.96M | +13.1% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $3.71M | +98.4% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $10.25M | n/a |
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $7.14M | +22.8% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $4.19M | -16.6% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $2.26M | -5.9% |
Compare TVGN, ELOX, BCDA, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗